TP53 and central nervous system cancer: Nearly all lower-grade gliomas with IDH mutations and no 1p/19q codeletion had mutations in TP53 (94%) and ATRX inactivation (86%) (Cancer Genome Atlas Research Network, Brat et al., 2015).